Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review.

doi:10.3390/v18080867

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review.

Viruses - 8 Aug 2026

Margot Nicolas A, Callebaut Christian

Abstract excerpt

Lenacapavir (LEN) is the first-in-class capsid inhibitor that inhibits HIV capsid function in vitro with picomolar activity. LEN has been approved for the treatment of HIV in combination with other antiretroviral agents (ARVs), as well as for the prevention of acquisition of HIV-1 in people who may benefit from pre-exposure prophylaxis (PrEP). In vitro investigations of the resistance profile of LEN have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Anti-HIV Agents
Share to Drug Resistance, Viral
Share to HIV-1
Share to HIV Infections
Share to Indazoles
Share to Mutation
Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 42655685
DOI: 10.3390/v18080867
PMCID: PMC13517945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics